Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.
Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.
Sells through hospitals, pharmacies and retail shelves: glucose sensors replaced every few weeks, diagnostics instruments with tests, heart and brain devices, and nutrition products. The sensors recur, which makes FreeStyle Libre a repeat-purchase growth line beside the one-off device sales.
Moat: wide (brand, installed base, scale). Leading positions across CGM, diagnostics and infant nutrition with strong brand loyalty and device ecosystems.
Headquarters: Abbott Park, Illinois, USA · Founded: 1888 · Employees: 115,000
Size Abbott Laboratories (ABT) is a United States Health Care company (Medical Specialties) with a market value of $181B, the 67th largest of 3,085 United States companies the cockpit tracks. Shares closed at $104.48 on 18 Nov 2026.
Performance Over six months the shares gained 18.2%, against +26.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 16 in its peer set.
Growth Revenue grew 10.0% over the last twelve months (peer median +8.9%); the operating margin is 14.2% (peer median 20.9%).
Valuation It trades at 17.9× forward earnings against a peer median of 25.6× (4th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.6 points below its cost of capital (7.4% WACC).
Credit Abbott Laboratories has 17 bonds outstanding ($30.3B), rated A+ by the agencies and trading like AA- at a weighted spread of 67 bp.
Short interest Short interest is 1.1% of the free float (30 Oct 2026).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $48.2B | $44.3B | $42.0B | $40.1B | $43.7B |
| Revenue growth | — | +6% | +5% | -8% | — |
| Gross profit | $25.2B | $23.4B | $21.3B | $20.0B | $22.3B |
| EBITDA | $10.8B | $11.4B | $10.1B | $9.68B | $11.6B |
| Net income | $4.72B | $6.50B | $13.4B | $5.70B | $6.91B |
| Free cash flow | $6.76B | $7.39B | $6.35B | $5.06B | $7.80B |
| Capital expenditure | $2.10B | $2.17B | $2.21B | $2.20B | $1.78B |
| Total debt | $31.2B | $14.1B | $15.3B | $15.9B | $17.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Dexcom DXCM | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Nestle NESN.SW | $258B | +8% | -2% | 16% | 19.1× | 1.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.0% | +5.2% | 6th lowest of 16 |
| 6-month return | +18.2% | +26.6% | 7th lowest of 16 |
| Distance from 52-week high | -20.0% | -7.2% | 6th lowest of 16 |
| Revenue growth (TTM) | +10.0% | +8.9% | 7th highest of 16 |
| Operating margin | 14.2% | 20.9% | 5th lowest of 16 |
| Forward P/E | 17.9× | 25.6× | 4th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 16.5% | 17.1% | 8th least demanding of 16 |
| Growth delivered (Del g) | +5.1% | +6.7% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | +11.4 pp | +6.0 pp | 6th most demanding of 16 |
| ROIC minus cost of capital | -0.6 pp | +1.9 pp | 6th lowest of 16 |
| EV / EBITDA | 19.3× | 22.6× | 8th cheapest of 16 |
| Net debt / EBITDA | 2.5× | 1.9× | 6th most indebted of 16 |
| Bond spread | 67 bp | 74 bp | 3rd tightest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | United States | $181B | +18% | +10% | 14% | 17.9× | 16.5% | +5.1% |
| Danaher DHR | United States | $161B | +34% | +6% | 21% | 25.1× | 20.8% | +2.0% |
| Intuitive Surgical ISRG | United States | $146B | -6% | +20% | 32% | 34.8× | 29.6% | +18.2% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Thermo Fisher Scientific TMO | United States | $257B | +53% | +8% | 19% | 25.7× | 21.3% | +6.7% |
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
Abbott Laboratories has 17 bonds outstanding with $30.3B face value. The agencies rate it A+; its bonds trade like AA-. Weighted yield 5.60%, a spread of 67 bp over government bonds.